Skip to content

Randomized Controlled Trial to assess the efficacy of a shielding method that utilises polyglycolic acid(PGA) sheets and fibrin glue to prevent bleeding after endoscopic submucosal dissection (ESD) for gastric neoplasms

Randomized Controlled Trial to assess the efficacy of a shielding method that utilises polyglycolic acid(PGA) sheets and fibrin glue to prevent bleeding after endoscopic submucosal dissection (ESD) for gastric neoplasms - PAGER BUSTER trial (Polyglycolic acid And fibrin Glue to ERadicate Bleeding Ulcer in the STomach Esd for Risked patients)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000015091
Enrollment
140
Registered
2014-09-09
Start date
2014-09-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer/gastric adenoma

Interventions

endoscopic tissue shielding method with PGA sheets and fibrin glue will be performed after gastric ESD. endoscopic tissue shielding method with PGA sheets and fibrin glue will not be performed after g

Sponsors

Graduate School of Medicine, University of Tokyo
Lead Sponsor
NTT Medical Center Tokyo, Takeda General Hospital, Sanraku Hospital, Tokatsu-Tsujinaka Hospital, Yokohama City University Medical Center
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Meet at least one of the following criteria of high risk bleeding after ESD. a)resection size would exceed 40mm because tumor size is expected to be >= 20mm. b)resection size would exceed 40mm because ulcer scar is inside the tumor. c)resection size would exceed 40mm because multiple adjacent lesions have to be resected in an en block fashion. d)taking oral antithrombotic drug. 2)Post-ESD ulcer scar is expected to be one lesion (irrespective of the number of tumors). 3)Preoperative pathological diagnosis of gastric cancer or adenoma is confirmed by endoscopic biopsy. 4)no evidence of metastasis on computed tomography. 5)Aged 20 years old or over. 6)PS (ECOG) of 0 to 2. 7)Meet all of the following criteria (without blood transfusion in the past 14 days). a) Hb >=9g/dl b) Plt >=100,000/mm3 c) AST,ALT <=100IU/l d) Cre <=2.0mg/dl 8)Available to be observed for at least 28 days after ESD. 9)With written informed consent.

Exclusion criteria

Exclusion criteria: 1)History of endoscopic treatment for upper GI lesion in the past 28 days. 2)With a scheduled endoscopic treatment for esophageal lesion or duodenal lesion concurrently. 3)With a scheduled endoscopic treatment for upper GI lesion in 28 days after gastric ESD. 4)with heparinization. 5)With an allergy to proton pomp inhibitor. 6)Pregnant or lactation woman. 7) History of myocardial infarction or unstable angina pectoris within 3 months. 8)With uncontrollable hypertension. 9)Patients whom investigators judge to be unsuitable for this trial.

Design outcomes

Primary

MeasureTime frame
post-ESD bleeding rate(from soon after ESD to 28 days after ESD)

Secondary

MeasureTime frame
1)late post-ESD bleeding rate(from meal commencement after ESD to 28 days after ESD) 2)blood transfusion rate associated with post-ESD bleeding 3)the rate of complications caused by PGA sheets or fibrin glue 4)risk factor for post-ESD bleeding 5)post-ESD bleeding rate in the patients whose resected specimen sizes are over 40mm 6)post-ESD bleeding rate in the cases where mucosal defects are shielding completely by PGA sheets 7)the rate of emergency endoscopy after ESD

Countries

Japan

Contacts

Public ContactYosuke Kataoka

Graduate School of Medicine, University of Tokyo Department of gastroenterology Laboratory No.108

ykataoka-nms@umin.org03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026